1. 木田圭亮. 急性心不全. 日本内科学会雑誌 2020;109:199-206
2. 筒井裕之. 心不全診療のスタンダード -診療ガイドラインをふまえて-. 臨牀と研究 96(3):1-6, 2019
3. 井手友美,筒井裕之. 新しい心筋症分類と拡張型心筋症-心筋症ガイドライン(2018年版)から-. Heart View 23(13):1130-1136, 2019
4. Kanaoka K, Okayama S, Nakai M, Sumita Y, Onoue K, Soeda T, Nishimura K, Kawakami R, Okura H, Miyamoto Y, Yasuda S, Tsutsui H, Komuro I, Ogawa H, Saito Y. Number of Cardiologists per Cardiovascular Beds and In-Hospital Mortality for Acute Heart Failure: A Nationwide Study in Japan. J Am Heart Assoc. 2019 Sep 17;8(18):e012282. doi: 10.1161
5. Kanaoka K, Okayama S, Nakai M, Sumita Y, Nishimura K, Kawakami R, Okura H, Miyamoto Y, Yasuda S, Tsutsui H, Komuro I, Ogawa H, Saito Y. Hospitalization Costs for Patients With Acute Congestive Heart Failure in Japan. Circ J. 2019 Apr 25;83(5):1025-1031. doi: 10.1253
6. McMurray J,(20名略) Kitakaze M,(16名略) and for the DAPH-HF trial investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019,381(21)1995-2008
7. Tadaki S,(14名略) Kitakaze M,(2名略), Factors alienating habitual exercise in patients with chronic heart failure -A multicenter prospective cohort study-. Heart Vessels,2020, 35(5):655-664
8. Hasegawa T,(9名略LA) Kitakaze MDifference in the prevalence of subclinical left ventricular impairment among left ventricular geometric pattern in a community-based population. Circ. J. 2020,75(4):439-446
9. Shindo K,(5名略LA) Kitakaze M, Plasma BNP levels and diuretics use as predictors of cardiovascular eventsin patients with myocardial infarction and impaired glucose tolerance. Cardiovasc. Drugs Ther.2020, 34(1):79-88
10. Ko T, Fujita K, Nomura S, Uemura Y, Yamada S, Tobita T, Katoh M, Satoh M, Ito M, Domoto Y, Hosoya Y, Amiya E, Hatano M, Morita H, Fukayama M, Aburatani H, Komuro I. Quantification of DNA Damage in Heart Tissue as a Novel Prediction Tool for Therapeutic Prognosis of Patients With Dilated Cardiomyopathy. JACC Basic Transl Sci. 2019 Sep 25;4(6):670-680. doi: 10.1016/j.jacbts.2019.05.010